

REMARKS

Preliminary to examination of this application, please amend claim 1, cancel claims 2-28 and add new claims 29-41. By the present amendment, claim 1, 29-41 are pending in the application. Support for the foregoing new claims can be found throughout the specification and drawings, and in the claims as originally filed. The above amendments introduce no new subject matter.

If there are any questions regarding the proposed amendments to the application, we invite the Examiner to call Applicants' representative at the telephone number below.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



DeAnn F. Smith, Esq.

Reg. No. 36,683

Attorney for Applicants

28 State Street
Boston, MA 02109
Tel. (617) 227-7400
Fax (617) 742-4214

Date: January 14, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION


On page 1, lines 4-8, please modify the paragraph as shown:

The present invention is a continuation of U.S. Serial No, 09/267,839, filed March 12, 1999, which is a continuation-in-part of PCT International Application No. PCT/US98/00440, filed January 7, 1998, designating the United States, which claims priority from U.S. Serial No. 60/035,826, filed January 8, 1997 and U.S. Serial No. 60/045,676, filed May 6, 1997, all of which are hereby expressly incorporated by reference.

IN THE CLAIMS:

Please amend claim 1 as follows:

1. (Amended) A compound having the formula:



wherein B [is selected from the group consisting of 2-amino-6-azidopurine, 2-amino-6-methoxypurine] is a heterocyclic ring derived from a purine or pyrimidine moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.